Selected research
Industry Research
Infliximab Injection Industry Research Report 2026
Market perspective
The global Infliximab Injection market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Infliximab Injection is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Infliximab Injection is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Infliximab Injection is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Infliximab Injection include Yuxi Jiahe Biotechnology, Taizhou Maiboteike Pharmaceuticals, Hangzhou Bozhirui Biopharmaceuticals, Pfizer, Nippon Kayaku, Nichiiko, Janssen Biologics, Celltrion and Ayumi Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Infliximab Injection market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Infliximab Injection Market by Company
Yuxi Jiahe Biotechnology
Taizhou Maiboteike Pharmaceuticals
Hangzhou Bozhirui Biopharmaceuticals
Pfizer
Nippon Kayaku
Nichiiko
Janssen Biologics
Celltrion
Ayumi Pharmaceuticals
AMGEN
Infliximab Injection Segment by Type
Original Drug
Generic Drug
Infliximab Injection Segment by Application
Hospital
Clinic
Other
Infliximab Injection Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Infliximab Injection market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Infliximab Injection and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Infliximab Injection.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Infliximab Injection manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Infliximab Injection by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Infliximab Injection in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Original Drug
- Generic Drug
Applications
- Hospital
- Clinic
- Other
Companies covered
- Yuxi Jiahe Biotechnology
- Taizhou Maiboteike Pharmaceuticals
- Hangzhou Bozhirui Biopharmaceuticals
- Pfizer
- Nippon Kayaku
- Nichiiko
- Janssen Biologics
- Celltrion
- Ayumi Pharmaceuticals
- AMGEN
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Infliximab Injection Market Size (2021-2032)
- 2.2.2 Global Infliximab Injection Sales (2021-2032)
- 2.2.3 Global Infliximab Injection Market Average Price (2021-2032)
- 2.3 Infliximab Injection by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Original Drug
- 2.3.3 Generic Drug
- 2.4 Infliximab Injection by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital
- 2.4.3 Clinic
- 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Infliximab Injection Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Infliximab Injection Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Infliximab Injection Revenue of Manufacturers (2021-2026)
- 3.4 Global Infliximab Injection Average Price by Manufacturers (2021-2026)
- 3.5 Global Infliximab Injection Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Infliximab Injection, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Infliximab Injection, Product Type & Application
- 3.8 Global Manufacturers of Infliximab Injection, Established Date
- 3.9 Global Infliximab Injection Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Yuxi Jiahe Biotechnology
- 4.1.1 Yuxi Jiahe Biotechnology Company Information
- 4.1.2 Yuxi Jiahe Biotechnology Business Overview
- 4.1.3 Yuxi Jiahe Biotechnology Infliximab Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Yuxi Jiahe Biotechnology Infliximab Injection Product Portfolio
- 4.1.5 Yuxi Jiahe Biotechnology Recent Developments
- 4.2 Taizhou Maiboteike Pharmaceuticals
- 4.2.1 Taizhou Maiboteike Pharmaceuticals Company Information
- 4.2.2 Taizhou Maiboteike Pharmaceuticals Business Overview
- 4.2.3 Taizhou Maiboteike Pharmaceuticals Infliximab Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Taizhou Maiboteike Pharmaceuticals Infliximab Injection Product Portfolio
- 4.2.5 Taizhou Maiboteike Pharmaceuticals Recent Developments
- 4.3 Hangzhou Bozhirui Biopharmaceuticals
- 4.3.1 Hangzhou Bozhirui Biopharmaceuticals Company Information
- 4.3.2 Hangzhou Bozhirui Biopharmaceuticals Business Overview
- 4.3.3 Hangzhou Bozhirui Biopharmaceuticals Infliximab Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Hangzhou Bozhirui Biopharmaceuticals Infliximab Injection Product Portfolio
- 4.3.5 Hangzhou Bozhirui Biopharmaceuticals Recent Developments
- 4.4 Pfizer
- 4.4.1 Pfizer Company Information
- 4.4.2 Pfizer Business Overview
- 4.4.3 Pfizer Infliximab Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Pfizer Infliximab Injection Product Portfolio
- 4.4.5 Pfizer Recent Developments
- 4.5 Nippon Kayaku
- 4.5.1 Nippon Kayaku Company Information
- 4.5.2 Nippon Kayaku Business Overview
- 4.5.3 Nippon Kayaku Infliximab Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Nippon Kayaku Infliximab Injection Product Portfolio
- 4.5.5 Nippon Kayaku Recent Developments
- 4.6 Nichiiko
- 4.6.1 Nichiiko Company Information
- 4.6.2 Nichiiko Business Overview
- 4.6.3 Nichiiko Infliximab Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Nichiiko Infliximab Injection Product Portfolio
- 4.6.5 Nichiiko Recent Developments
- 4.7 Janssen Biologics
- 4.7.1 Janssen Biologics Company Information
- 4.7.2 Janssen Biologics Business Overview
- 4.7.3 Janssen Biologics Infliximab Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Janssen Biologics Infliximab Injection Product Portfolio
- 4.7.5 Janssen Biologics Recent Developments
- 4.8 Celltrion
- 4.8.1 Celltrion Company Information
- 4.8.2 Celltrion Business Overview
- 4.8.3 Celltrion Infliximab Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Celltrion Infliximab Injection Product Portfolio
- 4.8.5 Celltrion Recent Developments
- 4.9 Ayumi Pharmaceuticals
- 4.9.1 Ayumi Pharmaceuticals Company Information
- 4.9.2 Ayumi Pharmaceuticals Business Overview
- 4.9.3 Ayumi Pharmaceuticals Infliximab Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Ayumi Pharmaceuticals Infliximab Injection Product Portfolio
- 4.9.5 Ayumi Pharmaceuticals Recent Developments
- 4.10 AMGEN
- 4.10.1 AMGEN Company Information
- 4.10.2 AMGEN Business Overview
- 4.10.3 AMGEN Infliximab Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 AMGEN Infliximab Injection Product Portfolio
- 4.10.5 AMGEN Recent Developments
5 Global Infliximab Injection Market Scenario by Region
- 5.1 Global Infliximab Injection Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Infliximab Injection Sales by Region: 2021-2032
- 5.2.1 Global Infliximab Injection Sales by Region: 2021-2026
- 5.2.2 Global Infliximab Injection Sales by Region: 2027-2032
- 5.3 Global Infliximab Injection Revenue by Region: 2021-2032
- 5.3.1 Global Infliximab Injection Revenue by Region: 2021-2026
- 5.3.2 Global Infliximab Injection Revenue by Region: 2027-2032
- 5.4 North America Infliximab Injection Market Facts & Figures by Country
- 5.4.1 North America Infliximab Injection Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Infliximab Injection Sales by Country (2021-2032)
- 5.4.3 North America Infliximab Injection Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Infliximab Injection Market Facts & Figures by Country
- 5.5.1 Europe Infliximab Injection Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Infliximab Injection Sales by Country (2021-2032)
- 5.5.3 Europe Infliximab Injection Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Infliximab Injection Market Facts & Figures by Country
- 5.6.1 Asia Pacific Infliximab Injection Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Infliximab Injection Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Infliximab Injection Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Infliximab Injection Market Facts & Figures by Country
- 5.7.1 South America Infliximab Injection Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Infliximab Injection Sales by Country (2021-2032)
- 5.7.3 South America Infliximab Injection Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Infliximab Injection Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Infliximab Injection Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Infliximab Injection Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Infliximab Injection Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Infliximab Injection Sales by Type (2021-2032)
- 6.1.1 Global Infliximab Injection Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Infliximab Injection Sales Market Share by Type (2021-2032)
- 6.2 Global Infliximab Injection Revenue by Type (2021-2032)
- 6.2.1 Global Infliximab Injection Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Infliximab Injection Revenue Market Share by Type (2021-2032)
- 6.3 Global Infliximab Injection Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Infliximab Injection Sales by Application (2021-2032)
- 7.1.1 Global Infliximab Injection Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Infliximab Injection Sales Market Share by Application (2021-2032)
- 7.2 Global Infliximab Injection Revenue by Application (2021-2032)
- 7.2.1 Global Infliximab Injection Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Infliximab Injection Revenue Market Share by Application (2021-2032)
- 7.3 Global Infliximab Injection Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Infliximab Injection Value Chain Analysis
- 8.1.1 Infliximab Injection Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Infliximab Injection Production Mode & Process
- 8.2 Infliximab Injection Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Infliximab Injection Distributors
- 8.2.3 Infliximab Injection Customers
9 Global Infliximab Injection Analyzing Market Dynamics
- 9.1 Infliximab Injection Industry Trends
- 9.2 Infliximab Injection Industry Drivers
- 9.3 Infliximab Injection Industry Opportunities and Challenges
- 9.4 Infliximab Injection Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst